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Cytochrome P450scc (CYP11A1) is a protein attached to the inner surface of the inner mitochondrial membrane that uses cholesterol
from the membrane phase as its substrate for the first step in steroid hormone synthesis. We investigated the mechanism by which CYP11A1
interacts with the membrane. Hydrophobicity profiles of CYP11A1 and two other mitochondrial cytochromes P450, plus a model structure of
CYP11A1 using CYP2C5 as template, suggest that CYP11A1 has a monotopic association with the membrane which may involve the AV
helix and the F–G loop. Deletion of the AVhelix reduced the proportion of expressed CYP11A1 associated with the bacterial membrane
fraction, indicating a role for the AVhelix in membrane binding. However, introduction of a cysteine residue in this helix at position 24 (L24C)
and subsequent labelling with the fluorescent probe NV-(7-nitrobenz-2-oxal,3-diazol-4-yl)ethylenediamine (NBD) failed to show a membrane
localisation. Cysteine mutagenesis and fluorescent labelling of other residues appearing on the distal surface of the CYP11A1 model revealed
that V212C and L219C have enhanced fluorescence and a blue shift following association of the mutant CYP11A1 with phospholipid
vesicles. This indicates that these residues, which are located in the F–G loop, become localised to a more hydrophobic environment
following membrane binding. Analysis of the quenching of tryptophan residues in CYP11A1 by acrylamide indicates that at least one and
probably two tryptophans are involved in membrane binding. We conclude that CYP11A1 has a monotopic association with the membrane
that is mediated, at least in part, by the F–G loop region.
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Cytochrome P450 side chain cleavage (CYP11A1) ca-
talyses the initial and rate-limiting step of steroid hormone
synthesis, the conversion of cholesterol to pregnenolone.
Cholesterol has extremely low solubility in water and
appears to be transferred to the active site of CYP11A1
from the inner mitochondrial membrane to which the
CYP11A1 is bound [1]. Determining the nature of the
interaction of CYP11A1 with the membrane is therefore
necessary to understand the catalytic mechanism and could
provide information for subsequent modification of the
membrane domain to facilitate protein crystallisation and0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.09.007
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University, Canberra 0200, ACT, Australia.structure determination. CYP11A1 is the best characterised
of the mitochondrial P450 enzymes with a large number of
published observations on the physical and catalytic prop-
erties of the enzyme. It therefore provides an excellent
model for structure–function studies of mitochondrial type
cytochromes P450.
Electron spin resonance studies have provided evidence
that the heme group of CYP11A1 is roughly parallel to the
plane of the membrane and is not embedded within the
hydrophobic membrane environment [2,3]. Hydrophobicity
profiles indicate that CYP11A1 lacks an N-terminal trans-
membrane anchor, a structural feature both predicted and
identified for microsomal P450s [4,5]. It has been suggested
that CYP11A1 is a transmembrane protein based on experi-
ments using antibodies to probe membrane topology in
mitochondria and using a transmembrane prediction algo-
rithm [6,7]. This is in contrast to results from trypsinolysis
experiments [8] as well as rotational diffusion and freeze-
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that CYP11A1 is tightly integrated but not transmembrane
[9,10]. The N-terminal half of CYP11A1 remains associated
with the mitochondrial membrane following partial tryptic
digestion and sodium carbonate extraction while the C-
terminal peptide is solubilised [11]. Removal of the N-
terminal membrane-binding domain of an engineered mi-
crosomal CYP2C5 has resulted in the crystallisation and
subsequent structure determination of the soluble domain of
an eukaryotic P450 [12]. In addition to the hydrophobic N-
terminal, there are likely to be other regions of membrane
interaction for microsomal P450s [12–14]. The crystal
structure of truncated CYP2C5 has surface residues mainly
from the N-terminal that include the F–G loop, residues
before the A helix and h strands 1–1 and 2–2 that may be
part of a secondary membrane-binding site.
The reconstitution of CYP11A1 into artificial phospho-
lipid vesicles provides a defined system for studying
CYP11A1 membrane interactions and has been used in
the present study. CYP11A1 incorporates into preformed
vesicles spontaneously [15,16] and all of the reconstituted
CYP11A1 molecules have an external adrenodoxin binding
site [1] and a heme orientation that is similar to CYP11A1 in
the mitochondrial membrane [2,3,17]. The reconstituted
CYP11A1 can bind and metabolise cholesterol from within
the vesicle bilayer [15,17,18]. In the present study we have
investigated the membrane topology of CYP11A1 using
methods of hydrophobicity profiling, secondary and tertiary
structure prediction, site-directed cysteine mutagenesis and
fluorescence spectroscopy. Our data reveal that residues
within the F–G loop of CYP11A1 are embedded in the
phospholipid membrane.2. Materials and methods
2.1. Materials
Tris-(2-carboxyethyl)phosphine hydrochloride and N,NV-
dimethyl-N-(iodoacetyl)-NV-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)ethylenediamine (IANBD) were from Molecular Probes
(Eugene, OR). The sources of other chemicals have been
described [19].
2.2. Hydrophobicity profiles
A multiple sequence alignment was generated for bovine
CYP11A1, human CYP11B1 and human CYP27A1 using
the T-Coffee alignment method which is particularly suited
to sequences of low identity [20]. The hydrophobicity
profile for each of the above sequences was determined
using the water to bilayer interfacial partitioning scale of
Wimley and White [21]. The hydrophobicity profile and
predicted membrane interfacial partitioning domains were
generated with the program MPEx (http://blanco.biomol.
uci.edu/mpex/index.html). The multiple alignment was thenemployed to generate a spreadsheet of the multiply aligned
hydrophobicity profile for the cytochrome P450 enzymes.
2.3. Modelling of CYP11A1
To aid with model selection and sequence alignment, the
secondary structure of CYP11A1 was predicted with Pro-
teinPredict. Of the known P450 structures, CYP2C5 [12]
has the highest sequence similarity to CYP11A1 with 21%
identity and was used as the template for the CYP11A1
model. The major advantage of using this microsomal P450
structure is the fact that it is the only membrane-bound P450
with known soluble domain structure. The disadvantage is
the lower resolution compared to the next most likely
homologues of CYP108 and CYP102. The N-terminal
hydrophobic anchor of CYP2C5 was deleted to aid crystal-
lisation, but the protein was still associated with the mem-
brane [22]. Poor homology exists between the N-terminal of
CYP2C5 and CYP11A1 whereas CYP108 has similar
secondary structure and length to that predicted for
CYP11A1. We therefore used CYP108 (1CPT.pdb) as a
structural template for the AV and A helices. Usanov et al.
[23] also used the N-terminal of CYP108 for their model of
CYP11A1 which used CYP102 as the general template
structure. Our model was generated using the Swiss Model
automated server and the heme group was modelled into the
heme-binding site by hand.
2.4. Mutagenesis and expression of bovine CYP11A1
Plasmid comprising the expression vector (pTrc99A)
and cDNA encoding bovine CYP11A1 was constructed
to contain coding sequence in a manner similar to that
described by Wada and Waterman [24]. Mutagenesis was
performed using the Quikchangek site-directed mutagen-
esis kit (Stratagene) with mutagenesis primers shown
in Table 1. The mutations were confirmed using auto-
mated Big-Dye Terminator DNA sequencing (Applied
Biosystems).
The wild-type plasmid described above was modified by
site-directed mutagenesis to substitute the one free cysteine
residue (C264) to serine. Serine is found in this position for
40% of known mitochondrial P450 enzymes. This C264S
mutant was then used as the template for subsequent site-
directed cysteine mutagenesis. The primers for the C264S
and subsequent cysteine mutants are listed in Table 1. Due
to the large number of residues of the CYP11A1 model that
are located on the distal side of the molecule, it was
unfeasible to modify all residues for analysis of membrane
interaction. We therefore made and analysed a number of
selected cysteine mutants with the aim of spanning regions
that might be associated with the membrane.
E. coli JM109 competent cells that had been prepared
using the RbCl2 method were transformed with the plasmid
encoding wild-type or mutant CYP11A1 [25]. A freshly
transformed isolate was prepared for expression culture as
Table 1
Oligonucleotides used to generate deletion and cysteine mutants of CYP11A1
Template Mutation Oligonucleotide
Wild type AVdelete 5V-CTCCCCTGGTGACAATGGCGGCTCACAGAGAATCCACTTTCGCC-3V
5V-GGCGAAAGTGGATTCTCTGTGAGCCGCCATTGTCACCAGGGGAG-3V
Wild type C-terminal delete 5V-CGCCGGACAAGCCCTGATTCCTTGTCTTCCGCC-3V
5V-GGCGGAAGACAAGGAATCAGGGCTTGTCCGGCG-3V
Wild type C264S 5V-GGCATCCTCTACTCCCTCCTGAAAAGTGAG-3V
5V-CTCACTTTTCAGGAGGGAGTAGAGGATGCC-3V
C264S N23C 5V-CAATGGCTGGCTTTGCCTCTACCATTTCTGGAGG-3V
5V-CCAGAAATGGTAGAGGCAAAGCCAGCCATTGTC-3V
C264S L24C 5V-GGTGACAATGGCTGGCTTAACTGCTACCATTTCTGGAGG-3V
5V-CTCCCTCCAGAAATGGTAGCAGTTAAGCCAGCCATTGTC-3V
C264S H26C 5V-GGCTTAACCTCTACTGTTTCTGGAGGGAGAAGGG-3V
5V-CTCCCTCCAGAAACAGTAGAGGTTAAGCCAG-3V
C264S N57C 5V-GAGAAGCTTGGCTGTTTGGAGTCAGTTTATATCATTCACC-3V
5V-GATATAAACTGACTCCAAACAGCCAAGCTTCTCCCTG-3V
C264S L58C 5V-CAGGGAGAAGCTTGGCAATTGTGAGTCAGTTTATATCATTCAC-3V
5V-CAGGGTGAATGATATAAACTGACTCACAATTGCCAAGCTTCTC-3V
C264S S60C 5V-CTTGGCAATTTGGAGTGTGTTTATATCATTCACCCTGAAG-3V
5V-GGTGAATGATATAAACACACTCCAAATTGCCAAGCTTC-3V
C264S Y94C 5V-GGCTGGCCTATCACCGATGTTATCAGAAACCCATTGG-3V
5V-GGACTCCAATGGGTTTCTGATAACATCGGTGATAGGCC-3V
C264S Y200C 5V-CCAGAAGTTCATTGATGCCGTCTGCAAGATGTTCCACAC-3V
5V-CACTGGTGTGGAACATCTTGCAGACGGCATCAATGAAC-3V
C264S V212C 5V-GTGTCCCTCTGCTCAACTGCCCTCCTGAACTGTAC-3V
5V-CGGTACAGTTCAGGAGGGCAGTTGAGCAGAGGGAC-3V
C264S L219C 5V-CCTCCTGAACTGTACCGTTGTTTCAGAACCAAGACTTGGAG-3V
5V-CCTCCAAGTCTTGGTTCTGAAACAACGGTACAGTTCAGGAG-3V
C264S V229C 5V-CCAAGACTTGGAGGGACCATTGTGCCGCATGGGACAC-3V
5V-GTGTCCCATGCGGCACAATGGTCCCTCCAAGTCTTGG-3V
C264S D233C 5V-CCATGTAGCCGCATGGTGCACAATTTTCAATAAAGCTG-3V
5V-CAGCTTTATTGAAAATTGTGCACCATGCGGCTACATGG-3V
C264S T234C 5V-GCATGGGACTGTATTTTCAATAAAGCTGAAAAATACACTGAGATC-3V
5V-CTTTATTGAAAATACAGTCCCATGCGGCTACATGG-3V
C264S N237C 5V-CACAATTTTCTGTAAAGCTGAAAAATACACTGAGATCTTCTACCAGG-3V
5V-GTGTATTTTTCAGCTTTACAGAAAATTGTGTCCCATGCGGC-3V
C264S T243C 5V-CAATAAAGCTGAAAAATACTGTGAGATCTTCTACCAGG-3V
5V-GGTAGAAGATCTCACAGTATTTTTCAGCTTTATTGAAAATTGTG-3V
C264S L460C 5V-GACGTGGACACCATATTCAACTGCATCCTGACGCCGG-3V
5V-GCTTGTCCGGCGTCAGGATGCAGTTGAATATGGTGTCC-3V
C264S L470C 5V-GGACAAGCCCATCTTCTGTGTCTTCCGCCCCTTC-3V
5V-GAAGGGGCGGAAGACACAGAAGATGGGCTTGTC-3V
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Luria Bertani culture and grown as previously described
except the expression time was shortened to 48 h for the
deletion mutants [27].
2.5. Purification of CYP11A1 from bovine adrenals and E.
coli
Native CYP11A1 was purified from bovine adrenals as
described previously [28]. The expressed wild-type enzyme
and the mutants were extracted from E. coli with 1%
Emulgen 913 and the insoluble debris was separated [29].
The detergent was then adsorbed to Amberlite XAD-2
(1.5 25 cm at flow 1 ml/min for 100-ml extract) equili-
brated with 20 mM potassium phosphate (pH 7.4), 20 mM
sodium chloride, 20% glycerol (Buffer A), containing 1 mM
DTT, 0.1 mM EDTA and CYP11A1 was collected in the
flow through. The enzyme solution was concentrated usingan Amicon concentrator with YM10 membrane and purified
by adrenodoxin Sepharose affinity chromatography [29].
Eluted enzyme was dialysed at 4 jC against 50 mM
potassium phosphate (pH 7.4), 50 mM sodium chloride,
20% glycerol, 0.03% cholate and 0.1 mM tris-(2-carbox-
yethyl)phosphine hydrochloride, concentrated and stored
substrate free at  80 jC. Cytochrome P450 concentrations
were determined from carbon monoxide reduced minus
reduced absorption spectra [30].
2.6. Cholesterol side chain cleavage assay
The activity of the CYP11A1 cysteine mutants incorpo-
rated into small unilamellar vesicles was determined at 37
jC using 0.03 AM CYP11A1, 10 AM adrenodoxin and 0.3
AM adrenodoxin reductase as described previously [19].
Vesicles were prepared from dioleoyl phosphatidylcholine,
cholesterol and cardiolipin in a molar ratio of 1:0.4:0.15.
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2.7. Distribution of CYP11A1 mutants between soluble and
membrane fractions
For analysis of the localisation of deletion mutants, the E.
coli cells were harvested, lysed and separated into a soluble
fraction, a membrane fraction and inclusion bodies [32].
Protein content for the soluble and membrane fractions and
inclusion bodies were determined using a Lowry assay [33].
Two modifications were made to maintain solubility and to
miniaturise the assay to volumes suitable for microtitre plate
wells. The assay was scaled to 250-Al final volume and 1%
SDS was included. The introduction of SDS did not alter the
sensitivity of the assay with bovine serum albumin used as
standard. The wild-type and mutant protein fractions were
separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) on a 7.5% gel, then transferred to a nitrocellulose
membrane for Western blot analysis [34] using antiserum
raised against bovine CYP11A1 [35]. Each fraction was
analysed by densitometry to determine the relative amounts
of immuno-reactive CYP11A1 using NIH Image 1.62. One
set of triplicate samples within the linear range of the
Western blot was used for the densitometric analysis for
each experiment.
2.8. Quenching of tryptophan fluorescence
To investigate whether any of the tryptophan residues
found in native CYP11A1 were associated with the mem-
brane, we tested the ability of acrylamide to quench the
fluorescence before and after CYP11A1 insertion into
vesicle membranes. Vesicles were prepared from egg phos-
phatidylcholine, cholesterol and cardiolipin in a molar ratio
of 1:0.2:0.15, by bath sonication as described previously
[19]. Vesicle-associated CYP11A1 was prepared in buffer
(pH 7.4) comprising 50 mM potassium phosphate, 130 mM
sodium chloride and 75 AM phospholipid. Aqueous or
vesicle-associated CYP11A1 (0.5 mM) was excited at 295
nm and fluorescence was measured for the emission wave-
lengths of 310 to 400 nm using a scan speed of 120 nm/min
with a Cary Eclipse fluorescence spectrophotometer (Var-
ian). Excitation and emission bandwidths were set to 5 nm
and temperature was maintained at 20 jC in a stirred quartz
cuvette with path length of 5 mm. Emission scans were
corrected for scatter by subtraction of buffer or vesicles as
appropriate. Acrylamide titrations were performed with
fixed excitation of 295 nm and an emission wavelength of
335 nm, with 5-nm bandwidths. Tryptophan fluorescence of
CYP11A1 was measured in the absence (F0) and then in the
presence (F) of increasing concentrations of acrylamide.
Fluorescence intensity was corrected for absorbance by
acrylamide as described previously [36] and for dilution
due to added quencher. The absorbance at 295 nm did not
exceed 0.07 during the titration. The quench constant (Kq)was determined using the Stern–Volmer plot from the
following equation:
F0=F ¼ 1þ Kq½Q
where F0 is the initial fluorescence intensity and F is the
intensity at each molar concentration of quencher [Q]. The
fraction of accessible tryptophan residues was analysed
using the Lehrer plot derived from a modified Stern–
Volmer equation [37]:
F0=DF ¼ 1=ðfKq½QÞ þ 1=f
where DF is the change in fluorescence due to quenching
and f is the fraction of initial fluorescence accessible to the
quencher.
2.9. Fluorescent labelling of CYP11A1 mutants
Prior to fluorescent labelling, CYP11A1 mutants (40
nmol) were exchanged into buffer (pH 7.4) comprising 50
mM potassium phosphate and 100 mM sodium chloride, by
gel filtration (G25 Sephadex, 0.75 20 cm). This removed
the glycerol prior to reaction since it is known to alter the
spin state and conformation of CYP11A1 and increase the
melting temperature of proteins [19,38], which could inhibit
labelling. All of the purified CYP11A1 mutants were stable
for the duration of the experiments in the absence of
glycerol. The CYP11A1 was then reacted with a 10-fold
molar excess of IANBD at room temperature according to
the manufacturer’s instructions. The labelled CYP11A1 was
purified by gel filtration using Buffer A containing 0.1%
cholate and 1 mM EDTA, and loaded onto an adrenodoxin
Sepharose column (0.75 2 cm). The column was washed
with 50 mM potassium phosphate and 1 mM EDTA (Buffer
B) until all unbound NV-(7-nitrobenz-2-oxa1,3-diazol-4-yl)e-
thylenediamine (NBD) had been removed. The NBD-la-
belled protein was then eluted with buffer B containing 1 M
sodium chloride and 10 AM 20a-hydroxycholesterol. The
concentrations of NBD and CYP11A1 were determined
spectrophotometrically, with extinction coefficients of
27,300 [39] and 110,000 M 1 cm 1 at 478 and 404 nm,
respectively. The NBD concentration was calculated after
correction for the absorbance contribution due to CYP11A1
at 478 nm.
2.10. Half-time for vesicle association and steady state
fluorescence
The fluorescence for soluble and vesicle-bound
CYP11A1-NBD was measured in a stirred cuvette at 20 jC
with excitation at 480 nm and emission at 535 nm with 5-
nm bandwidths. The fluorescence was corrected for scatter
as described for tryptophan fluorescence and the ratio of
membrane-bound to soluble fluorescence intensity was
determined for the NBD-labelled wild-type and mutant
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concentrations were as for measurements of acrylamide
quenching of tryptophan fluorescence except the vesicles
comprised of egg phosphatidylcholine, 20a-hydroxycholes-
terol and cardiolipin in a molar ratio of 1:0.15:0.15. The
fluorescence intensity was measured as a function of time
from the addition of vesicles and a single exponential curve
was fitted for the fluorescence change for the combined data
of duplicate experiments for each CYP11A1 mutant. A
small change (2%) in fluorescence due to vesicle scatter
occurred following mixing of CYP11A1-NBD and vesicles
but was very rapid and did not interfere with half-time
measurements for CYP11A1-NBD association with
vesicles. The half-time for the association of unlabelled
CYP11A1 with vesicles containing cholesterol was also
measured for some CYP11A1 mutants, using the spin state
change that accompanies cholesterol binding [15,16]. Con-
centrations and conditions were as for measurement of
tryptophan fluorescence.3. Results
3.1. Hydrophobicity profiles of mitochondrial cytochromes
P450
The multiply aligned interfacial hydrophobicity profiles
of CYP11A1 and two other mitochondrial P450 enzymes
are illustrated in Fig. 1. The labelled regions of the E, F, H
and I helices, the F–G loop and h 2–1 and 2–2 are
potential membrane interfacial binding regions for all threeFig. 1. Multiply aligned hydrophobicity profiles of mitochondrial cytochromes
generation of the profiles with regions of sequence that have a favourable DG for m
values are for mature sequences of bovine CYP11A1 (thick solid line), human CYP
the sequence number for the multiple alignment. Putative secondary structure feamitochondrial cytochromes CYP11A1, 11B1 and 27A1.
The hydrophobicity trends are generally consistent for the
mitochondrial cytochromes P450 although there are consid-
erable differences in the amplitude of the DG predicted for
localisation from water to membrane interface. Interestingly,
the regions of common prediction are also consistently
found in other mitochondrial cytochromes P450. The profile
for the N-terminal and F–G loop of CYP27A1 is clearly
different from the more similar profiles of CYP11A1 and
CYP 11B1. In the case of CYP27A1, the AVhelix contains a
series of phenylalanine residues that elevate the overall
hydrophobicity of this region compared to the AV helix of
CYP11A1. The F–G loop region of CYP11A1 and 11B1
enzymes have an amphipathic character that results in
reduced hydrophobicity compared with CYP27A1.
3.2. CYP11A1 model
The sequence alignment used for modelling CYP11A1 is
shown in Fig. 2. The template only contains sequence that
has resolved structure and therefore some residues are not
present for the template sequence. The sequence alignment
includes some minor adjustment to incorporate secondary
structure predictions for CYP11A1. The BV helix is not
found in CYP2C5 but was predicted for the mitochondrial
P450 isoforms examined (CYP11A1, 11B1, 24 and 27A1;
results not shown) and therefore may be a secondary
structure feature that will be present in these enzymes.
The recently published mutagenesis and modelling study
of CYP11A1 using CYP102 as template did include a BV
helix for CYP11A1 [23]. The putative F–G loop ofP450. The hydrophobicity scale of Wimley and White [20] was used for
embrane interfacial partitioning being indicated with a bar. Hydrophobicity
11B1 (thin line) and human CYP27A1 (dashed line) and are plotted against
tures are labelled.
Fig. 2. Sequence alignment of CYP11A1 and the modelling template sequence of CYP2C5. Primary sequence was aligned for CYP11A1 and CYP2C5, except
for the AV and A helix regions where the residues of CYP108 (1CPT.pdb) were used as template up to the C-terminal of the A helix. Alpha helices are
underlined and beta sheet structures are double-underlined in the positions corresponding to the CYP2C5 structure (1DT6.pdb).
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structure known and was not predicted to have defined
secondary structure. The F–G loop for CYP2C5 is approx-
imately five residues shorter from the F helix to G-helix than
that predicted for CYP11A1 and 10 of the residues for
CYP2C5 were ambiguous in the crystal structure (Fig. 2).
The sequence for the F–G loop region of CYP2C5 in
particular is absent and Swiss-model has inserted a loop
region from the loop database to accommodate the sequence
length of CYP11A1. We consider the structure for this part
of the molecule to be speculative but it is unlikely to
traverse a membrane. The region most likely to interact
with the membrane domain is the distal face of CYP11A1
shown in Fig. 3, which has an aromatic region surrounding
a hydrophobic patch in the vicinity of the F–G loop. The
CYP11A1 model highlighting tryptophan residues (space
filled) that may be located within the putative membrane-
binding domain is shown in Fig. 3. The proximal or
adrenodoxin binding face of the CYP11A1 model has an
overall positive charge. K338 and K342 have been impli-
cated in adrenodoxin binding [23] but in our model these
residues are recessed from the surface of the molecule,
suggesting that they do not directly interact with adreno-
doxin. These residues have a similar recessed location in
the CYP11A1 model developed by Usanov et al. [23].Other residues (K267, K403, K405 and R426) that are
believed to be involved in adrenodoxin interaction [23] are
all located on the proximal surface of our model. Our
model is expected to have minor differences to the model
of Usanov et al. [23] due to the different template
structures used [40]. The major differences are likely to
be within the distal face, in the regions of the B–C loop,
the interior of the F and G helices, and beta sheet 4.
Procheck was used to analyse the stereochemical qual-
ity of the model. The results for the CYP11A1 model
indicate that over 73% of residues are in the most favoured
regions of the Ramachandran plot and 2.4% in disallowed
regions while CYP2C5 had over 71% in allowed and 1.8%
in disallowed regions. The model appears to be consistent
with available data on CYP11A1 and stereochemistry is of
comparable quality to the template. We consider the model
as a useful tool for identification of the membrane-binding
or distal domain of CYP11A1. The sites for deletion
mutations were at the N- and C-terminal and the cysteine
mutants were chosen within the AV helix, BV helix, F–G
loop, G helix and in the beta sheet region at the C-terminal
of CYP11A1. The E, H and I helices were not analysed
because they do not appear on the distal surface of our
CYP11A1 model. The AV helix was investigated for pos-
sible membrane interaction because it is located at the
Fig. 3. Modelled Structure of CYP11A1. A ribbon diagram of the
CYP11A1 model structure viewed from the distal surface that is putatively
the membrane binding domain (approximately parallel to the plane of the
figure). The heme is roughly parallel to the membrane domain and
tryptophan residues located on the distal surface are space filled. Some of
the relevant secondary structures are labelled. The diagram was prepared
with MolMol [51].
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microsomal cytochromes P450. The BV helix has been
previously implicated in cholesterol interaction [41] and,
from our model, is located on the putative membrane-
binding face of cytochrome CYP11A1.
3.3. Characterisation of CYP11A1 mutants
The N- and C-terminal deletion mutants were expressed
as spectrally stable, low spin enzyme in E. coli membranes,
but were unstable during recording of the CO-reduced
minus reduced difference spectra where partial denaturation
to P420 occurred. These mutants proved to be unstable
during extraction and purification. Most of the cysteine
mutants were stable as judged from their CO-reduced minus
reduced difference spectra and we typically purified 100 to
200 nmol from 1 l of culture. The expressed mutants that
were unstable and therefore not purified in sufficient quan-
tities for fluorescence analysis were H26C, Y200C, D233C
and L470C. Y200C and L470C were denatured during
extraction and purification. The mutant N23C was
expressed and purified but found to be unstable during
chemical labelling with IANBD. To test their structural
integrity, all mutants that were purified, including N23C,
H26C and D233C, were examined for their ability to display
a type 1 spectral response (a shift to a higher spin state) inresponse to binding cholesterol from the vesicle membrane.
All mutants displayed a typical type 1 response (data not
shown), indicating they can access membrane cholesterol
and have a functional active site in terms of the spin state of
the heme. To further check structural integrity, we measured
the maximum velocity of wild-type CYP11A1 and key
mutants including C264S, L58C, V212C, L219C, V229C,
and N237C, which all had turnover numbers (kcat) of
approximately 20 min 1, similar to that of the native
enzyme purified from bovine adrenals (17 min 1). The
L460C mutant had a very low turnover number of 0.5
min 1. Other mutants were not tested for activity. C264S,
V212C, L219C and V229C had half-times of 3.5 to 4 min
for association with vesicles containing cholesterol, mea-
sured from the spin-state change. Both expressed wild-type
CYP11A1 and C264S had Km values for adrenodoxin of
1.6F 0.2 AM.
3.4. Distribution of CYP11A1 between the membrane and
soluble fractions of E. coli
The distribution of microsomal P450 enzymes has been
assessed by fractionation of E. coli into soluble and
membrane fractions following the truncation of the N-
terminal hydrophobic anchor [32,42]. In a similar ap-
proach, mutants of mitochondrial cytochrome P45027A1
were analysed by Western blot analysis following E. coli
fractionation in order to identify critical residues involved
in membrane binding [43,44]. We have likewise made use
of Western blot analysis to measure the effect of CYP11A1
N- and C-terminal deletion mutations on membrane local-
isation (Fig. 4). The E. coli membranes of the expressed
wild type, AV helix deletion and C-terminal deletion
(I468STOP) mutants of CYP11A1 contained 76F 13%,
47F 9% and 86F 18% of the combined membrane and
cytosolic CYP11A1 content, respectively. The amount of
CYP11A1 detected in the inclusion body fraction was
approximately 12% for the wild type and both deletion
mutants. Two separate experiments analysed in triplicate
gave similar results, indicating decreased membrane asso-
ciation of the AV helix deletion mutant and no change in
localisation of the C-terminal deletion mutant compared to
wild-type CYP11A1.
3.5. Steady-state tryptophan fluorescence of membrane
associated CYP11A1
Soluble CYP11A1 has an emission maximum at ap-
proximately 338 nm for the excitation of tryptophan
residues at 295 nm. This maximum is indicative of
relatively non-polar tryptophan residues as observed by
others [6,45]. For vesicle-associated CYP11A1 where
tryptophan fluorescence has not been measured before,
the emission maximum was at 337 nm, similar to the
soluble enzyme. This implies that there is no major change
in average hydrophobicity of the nine tryptophan residues
Fig. 5. Tryptophan fluorescence quenching in the presence and absence of
phosphatidylcholine vesicles. (A) Acrylamide quenching of tryptophan
residues of soluble (circles) and membrane-associated CYP11A1 (crosses)
were analysed using the Stern–Volmer plot. (B) Lehrer plot of tryptophan
fluorescence change versus the inverse of acrylamide concentration. The
intercept on the F0/DF axis gives the inverse of the fraction of accessible
tryptophan residues for the soluble (circles) and vesicle-bound (crosses)
CYP11A1.
Fig. 4. Western blot analysis of the distribution of N- and C-terminal deletion mutants of CYP11A1 between membrane and soluble fractions of E. coli.
Following fractionation, triplicates of samples were subjected to SDS-PAGE, transferred to nitrocellulose and probed with anti-bovine CYP11A1 antiserum.
Amounts of sample applied were: wild type, 2 Ag membrane, 10 Ag soluble; A’ delete, 2 Ag membrane, 2 Ag soluble; I468STOP, 10 Ag membrane, 20 Ag
soluble fraction.
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membrane.
3.6. Tryptophan fluorescence quenching by acrylamide
CYP11A1 in solution and in vesicles gave a linear plot of
F0/F versus [Q], suggesting a single type of quenching
mechanism by acrylamide. There were typical quench con-
stants (Ksv) of 2.12F 0.04 M
 1 for soluble CYP11A1 and
1.88F 0.04 M 1 for vesicle associated enzyme (Fig. 5A).
The number of accessible tryptophan residues was signifi-
cantly reduced (P < 0.05) from 8.6F 0.7 to 7.0F 0.4 for the
membrane-bound enzyme when compared with soluble
enzyme (Fig. 5B). The soluble enzyme has previously been
observed to have a dynamic quenching mechanism with
quench constant of 1.52 M 1 at 20 jC with essentially all
nine tryptophan residues exposed to acrylamide quenching
[45]. Our results indicate that at least one and more likely
two of the quenchable tryptophan residues of soluble
CYP11A1 become inaccessible to acrylamide quenching
following membrane association.
3.7. Half-time for the CYP11A1-NBD fluorescence change
associated with incorporation into vesicles
The fluorescence of soluble CYP11A1-NBD was low for
all mutants and increased with time following the addition
of vesicles in a manner giving a good fit to a single
exponential curve, indicating a first-order or pseudo-first-
order process (Fig. 6). A single exponential curve gave a
superior fit to a bi-exponentional function, which was also
tested. The fluorescence change appears to give a measure
of the rate of association of the protein with the vesicles (see
Discussion). Similar measurements have been used to char-
acterize the rate of association of other proteins with
membranes and to determine the rate of ligand binding
[39,46,47]. The wild-type CYP11A1-NBD was estimated to
have a half-time of approximately 0.8 min for the fluores-
cence change following mixing with phosphatidylcholine
vesicles containing 20a-hydroxycholesterol. Two F–G loop
mutants, V212C-NBD and L219C-NBD, had significant
increases in the half-time for the fluorescence change
Fig. 6. Time course for the change in NBD fluorescence with association of
CYP11A1 with vesicles. Fluorescence of NBD-labelled CYP11A1 (0.5
AM) was monitored during the association of CYP11A1 with small
unilamellar vesicles. Fluorescence (excitation 480 nm and emission 535
nm) was measured at 20 jC in a stirred quartz cuvette with a path length of
5 mm. A single exponential curve was fitted to the data.
M.J. Headlam et al. / Biochimica et Bio104following mixing with vesicles (Fig. 7). These mutations
occur in the putative F–G loop of CYP11A1 and showed a
2- to 2.5-fold increase in half-time compared with those for
wild-type CYP11A1-NBD. Other CYP11A1 mutants that
we tested did not have significantly different half-times to
that for wild-type CYP11A1.Fig. 7. Fluorescence characteristics of CYP11A1 cysteine mutants labelled with N
addition of phospholipid vesicles to soluble CYP11A1. Error bars areF standard
ratio of relative fluorescence of membrane bound to soluble CYP11A1. Error bars a
for P< 0.05 or P < 0.005 from wild type are marked with * or **, respectively.3.8. Relative fluorescence of P450-NBD in solution and in
the presence of vesicles
After membrane incorporation was complete, the ratio of
relative fluorescence in vesicle to the relative fluorescence of
soluble CYP11A1-NBD (F(vesicle/soluble)) was signifi-
cantly increased for V212C-NBD and L219C-NBD com-
pared to wild-type CYP11A1-NBD. The low fluorescence of
the NBD-labelled P450 mutants in solution indicates that the
environmentally sensitive NBD exists in a relatively hydro-
philic environment. The increase in fluorescence observed
for V212C-NBD and L219C-NBD indicates the NBD is
localised to a more hydrophobic environment following
membrane association. This is consistent with aqueous
exposed NBD becoming buried within the acyl chain region
of the phospholipids as the CYP11A1 incorporates into the
vesicle membrane. The low emission maxima for the
V212C-NBD and L219C-NBD (Fig. 8) indicate that the
soluble enzyme provides a relatively hydrophobic environ-
ment for the bound NBD. Following membrane binding,
there is a blue shift in emission that indicates an even more
hydrophobic environment for the bound NBD which is also
consistent with the relocation of residues V212C and L219C
into the hydrophobic acyl chains of the membrane. As the
distance from the F–G loop increases, mutations predicted to
be in the G helix (V229C, T234C, N237C and T243C) show
increasing hydrophilic exposure as indicated by the NBD
emission maxima (Fig. 8). G helix residues show a moderate
blue shift following membrane association of the NBD
labelled CYP11A1 mutants, which demonstrates a sensitiv-
ity to binding, but not a change in exposure, to the quenching
physica Acta 1617 (2003) 96–108BD. Filled bars are the half-times for the increase in fluorescence following
deviation of the curve fit for two combined experiments. Open bars are the
reF standard deviation of 4 experiments. Results with significant difference
Fig. 8. Fluorescence emission characteristics of CYP11A1 cysteine mutants labelled with NBD. Open and filled bars represent the emission maxima for soluble
NBD-CYP11A1 and membrane-bound NBD-CYP11A1, respectively. The excitation maximum was 480 nm with emission scanned from 500 to 600 nm at a
rate of 120 nm/min. Other conditions were as for Fig. 6.
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affected by membrane binding than the F–G loop and G
helix.4. Discussion
A common first step to identifying membrane domains of
proteins is to estimate the hydrophobicity of the primary
sequence using available prediction algorithms. While to-
pology prediction has correctly identified an N-terminal
membrane anchor in microsomal P450s, no transmembrane
segment was predicted for CYP11A1 using either the
Engleman or Kyte and Doolittle scales of hydrophobicity
[4]. Experimental evidence indicates that CYP11A1 is not
likely to be transmembrane but is membrane-bound through
hydrophobic interaction. The hydrophobicity plot in Fig. 1
was generated with the hydrophobicity scale of Wimley and
White [21] and several possible interfacial membrane
domains were predicted for the mitochondrial cytochromes
P450. The Wimley–White hydropathy scale predicts mem-
brane proteins with up to 99% accuracy by accounting for
the energetic cost of burying an entire residue within a
membrane or membrane interface environment rather than
just the side chain of the residue. We made use of this
algorithm to assist with identification of hydrophobic
stretches of amino acids that may be involved in membrane
binding but that do not necessarily span the membrane.
Hydrophobicity scales can result in false predictions, as has
been reported for some internal hydrophobic helices of
extramembrane proteins [48]. Most notably, the I helix is
unlikely to interact with the membrane and is almost
certainly an internal hydrophobic helix, as observed forthe highly conserved tertiary structure seen for CYP101,
CYP108, CYP107A, CYP102, CYP2C5, and CYP51. Anal-
ysis of the hydropathy profile in Fig. 1 for interfacial
membrane binding of mitochondrial P450 enzymes in the
regions of the predicted AV helix and F–G loop reveals
elevated hydrophobicity of CYP27A1. Expression studies
on CYP27A1 have shown that it is entirely associated with
the membrane fraction of E. coli cells [44] while we have
shown that only 75% of CYP11A1 is associated with the
membranes. As noted by Murtazina et al. [44], CYP27A1
requires higher detergent concentrations for solubilisation
from the membrane compared with that required for
CYP11A1 solubilisation. This may explain the greater
relative hydrophobic interaction seen experimentally [44].
The reduced hydrophobicity of CYP11A1 compared with
other mitochondrial P450 enzymes, and in particular
CYP27A1, may facilitate crystallisation of this enzyme. In
the case of CYP2C5, crystallisation of the enzyme followed
the introduction of mutations that induced monomerisation
of the enzyme [12,22]. Further work is required with the
mitochondrial P450 enzymes to explore the potential gains a
similar approach might provide.
Evaluation of our molecular model of CYP11A1 in
concert with hydrophobicity profiles gives rise to the hypoth-
esis that the AVhelix and the F–G loop region are involved in
membrane binding. In the absence of a transmembrane
domain, it appears reasonable to suggest that the AV helix
would lie within the interfacial region of themembrane lipids.
The reduced proportion of CYP11A1 associated with the E.
coli membrane fraction for the AV helix deletion mutant
supports this hypothesis. We made three cysteine mutants
to examine this hypothesis further, only to find that H26Cwas
unstable and could not be purified, N23C was stable enough
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and only L24C was stable for purification and labelling with
NBD. The environmentally sensitive NBD bound to L24C
gave no evidence of being buried in a hydrophobic environ-
ment in the presence of vesicles. This mutant gave a typical
high spin transition when added to vesicles containing
cholesterol, indicating vesicle association had occurred.
The AV helix is almost certainly found on the surface of
CYP11A1 but further study is required to determine whether
it is involved in membrane interaction. There is only moder-
ate sequence identity among the mitochondrial cytochromes
P450 within the AV helix, whereas there is high sequence
identity in this region for cytochromes CYP11A1 and 11B1
for all species with known sequence (results not shown). Our
results show that two out of three mutations within the
putative AV helix caused structural instability of CYP11A1,
indicating an important structural role for this region of the
molecule that may be specific to CYP11A1 and closely
related mitochondrial cytochromes P450.
Cysteine mutagenesis and NBD labelling strongly sup-
port the hypothesis that the F–G loop region of CYP11A1 is
embedded in the hydrophobic membrane domain. The F–G
loop mutants V212C and L219C gave increased NBD
fluorescence upon vesicle association, indicating a shift to
a more hydrophobic environment. This is the first time that
it has been shown that residues of the F–G loop of a
mitochondrial cytochrome P450 integrate into the mem-
brane environment. Residue V229 and other residues C-
terminal of this that are probably located in the G helix, do
not appear to be located in the hydrophobic membrane
domain but are sensitive to membrane association. Our
evidence therefore suggests that unless there are gross
conformational differences between the known P450 struc-
tures and CYP11A1 in the vicinity of the F helix, then there
is not a long enough stretch of amino acids in the F–G loop
to generate a transmembrane domain. This is in support of
the major body of evidence indicating a monotopic associ-
ation of CYP11A1 with vesicles [9,10].
As well as showing increased NBD fluorescence and
relocation to a more hydrophobic environment, the F–G loop
mutants V212C and L219C displayed a slower rate of
fluorescence change than wild-type CYP11A1 on mixing
with vesicles. We have previously measured the rate of
incorporation of CYP11A1 into phospholipid vesicles from
the change in spin state that accompanies cholesterol binding
or dissociation [15]. Using this technique, we checked the
rate of association with vesicles of unlabelled wild-type
CYP11A1 as well as the V212C and L219C mutants and
found that their half-times were similar (results not shown).
Half-times were slower than for the fluorescence change of
NBD-labelled wild-type CYP11A1 following mixing with
vesicles but were similar to the values for NBD-labelled
V212C and L219C. We suggest that the fluorescence change
observed for NBD-labelled V212C and L219C provides a
measure of the rate of integration of the CYP11A1 into the
hydrophobic membrane phase while the fluorescence changefor NBD-labelled wild-type CYP11A1 and the other mutants
examined measures peripheral association with the mem-
brane, but not integration. This interpretation is supported by
studies on colicin association with vesicles, which was
examined using cysteine mutagenesis with subsequent label-
ling and EPR analysis [46]. Colicin showed a rapid initial
association with vesicles followed by a slower insertion phase
and the two events could be distinguished by the position of
the labelled residue in the protein.
We have detected a change in environment of tryptophan
residues of CYP11A1 upon membrane association consistent
with the important function aromatic amino acids play in
membrane interfacial binding [49,50]. Examination of our
model structure indicates that four of the nine tryptophan
residues are located on the distal face of CYP11A1. We can
therefore predict that the two tryptophan residues detected to
have reduced exposure to acrylamide due to membrane
association could be any two of W21, W28 of the AVhelix
andW225 andW232 of the F–G loop andG helix.We cannot
exclude the involvement of all four tryptophan residues in
membrane association but only an average of approximately
two of these have altered accessibility to the aqueous fluo-
rescence quencher, acrylamide. Our results from cysteine
mutagenesis and labelling reveal that V212 and L219 are
membrane-integrated while the nearby residues V229, T234,
N237 and T243 are not. From this and our model structure, it
seems possible that W225 is integrated within the membrane,
being in closest proximity to L219. The residue W232 is less
likely to be integrated because it is located between residues
that are not within in the hydrophobic membrane domain.
Our data suggest that the F–G loop region is the primary
site of interaction of mitochondrial P450s with the mem-
brane. Unlike mitochondrial cytochromes P450, microsomal
P450 enzymes have a primary site of membrane interaction in
the form of a single transmembrane anchor at the N-terminal
[14]. There is evidence that the F–G loop is a secondary site
of interaction of microsomal P450s with the membrane [50].
The mitochondrial P450 enzymes have an extended F–G
loop region compared to microsomal P450s, which acts to
provide an improved DG that can in part compensate for the
absence of a transmembrane anchor. It remains to be seen if
additional regions of CYP11A1 and other mitochondrial
cytochromes P450 are buried within the membrane.Acknowledgements
We thank Dr. Kevin Croft from the University of Western
Australia, Department of Medicine, for the use of the
fluorometer, Dr. Dharharajan for the cDNA for bovine
CYP11A1 and Dr. Guido Pintacuda for assistance with the
program MolMol. We also thank Dr. Eric Johnson for
providing the coordinates of CYP2C5 prior to their release
through the Research Collaboratory for Structural Bioinfor-
matics Protein Databank. This work was supported by a
University of Western Australia Small Grant (to RCT).
M.J. Headlam et al. / Biochimica et Biophysica Acta 1617 (2003) 96–108 107References[1] D.W. Seybert, J.J. Lancaster, J.D. Lambeth, H. Kamin, Participation
of the membrane in the side chain cleavage of cholesterol. Reconsti-
tution of cytochrome P-450scc into phospholipid vesicles, J. Biol.
Chem. 254 (1979) 12088–12098.
[2] H. Blum, J.S. Leigh, J.C. Salerno, T. Ohnishi, The orientation of
bovine adrenal cortex cytochrome P-450 in submitochondrial particle
multilayers, Arch. Biochem. Biophys. 187 (1978) 153–157.
[3] H. Kamin, C. Batie, J.D. Lambeth, J. Lancaster, L. Graham, J.C.
Salerno, Paramagnetic probes of multicomponent electron-transfer
systems, Biochem. Soc. Trans. 13 (1985) 615–618.
[4] D.R. Nelson, H.W. Strobel, On the membrane topology of vertebrate
cytochrome P-450 proteins, J. Biol. Chem. 263 (1988) 6038–6050.
[5] G. Vergeres, K.H. Winterhalter, C. Richter, Identification of the mem-
brane anchor of microsomal rat liver cytochrome P-450, Biochemistry
28 (1989) 3650–3655.
[6] P. Anzenbacher, J. Hudecek, S. Vajda, V. Fidler, C. Larroque, R.
Lange, Nanosecond fluorescence of tryptophans in cytochrome P-
450scc (CYP11A1): effect of substrate binding, Biochem. Biophys.
Res. Commun. 181 (1991) 1493–1499.
[7] S.A. Usanov, A.A. Chernogolov, V.L. Chashchin, Is cytochrome P-
450scc a transmembrane protein? [published erratum appears in FEBS
Lett 1991 Mar 25;280(2):400] FEBS Lett. 275 (1990) 33–35.
[8] P.F. Churchill, T. Kimura, Topological studies of cytochromes P-
450scc and P-45011 beta in bovine adrenocortical inner mitochondrial
membranes. Effects of controlled tryptic digestion, J. Biol. Chem. 254
(1979) 10443–10448.
[9] D. Schwarz, V. Kruger, A.A. Chernogolov, S.A. Usanov, A. Stier,
Rotation of cytochrome P450SCC (CYP11A1) in proteoliposomes
studied by delayed fluorescence depolarization, Biochem. Biophys.
Res. Commun. 195 (1993) 889–896.
[10] D. Schwarz, W. Richter, V. Kruger, A. Chernogolov, S. Usanov, A.
Stier, Direct visualization of a cardiolipin-dependent cytochrome
P450scc-induced vesicle aggregation, J. Struct. Biol. 113 (1994)
207–215.
[11] W.J. Ou, A. Ito, K. Morohashi, Y. Fujii-Kuriyama, T. Omura, Pro-
cessing-independent in vitro translocation of cytochrome P-450(SCC)
precursor across mitochondrial membranes, J. Biochem. (Tokyo) 100
(1986) 1287–1296.
[12] P.A. Williams, J. Cosme, V. Sridhar, E.F. Johnson, D.E. McRee,
Mammalian microsomal cytochrome P450 monooxygenase: structur-
al adaptations for membrane binding and functional diversity, Mol.
Cell 5 (2000) 121–131.
[13] S.J. Pernecky, N.M. Olken, L.L. Bestervelt, M.J. Coon, Subcellular
localization, aggregation state, and catalytic activity of microsomal
P450 cytochromes modified in the NH2-terminal region and ex-
pressed in Escherichia coli, Arch. Biochem. Biophys. 318 (1995)
446–456.
[14] M.L. Shank-Retzlaff, G.M. Raner, M.J. Coon, S.G. Sligar, Membrane
topology of cytochrome P450 2B4 in Langmuir –Blodgett mono-
layers, Arch. Biochem. Biophys. 359 (1998) 82–88.
[15] R.C. Tuckey, H. Kamin, Kinetics of the incorporation of adrenal
cytochrome P-450scc into phosphatidylcholine vesicles, J. Biol.
Chem. 257 (1982) 2887–2893.
[16] P. Kisselev, R. Wessel, S. Pisch, U. Bornscheuer, R.D. Schmid, D.
Schwarz, Branched phosphatidylcholines stimulate activity of cyto-
chrome P450SCC (CYP11A1) in phospholipid vesicles by enhancing
cholesterol binding, membrane incorporation, and protein exchange,
J. Biol. Chem. 273 (1998) 1380–1386.
[17] J.D. Lambeth, D.W. Seybert, H. Kamin, Phospholipid vesicle-recon-
stituted cytochrome P-450SCC. Mutually facilitated binding of cho-
lesterol and adrenodoxin, J. Biol. Chem. 255 (1980) 138–143.
[18] D. Schwarz, P. Kisselev, R. Wessel, O. Jueptner, R.D. Schmid, Alpha-
branched 1,2-diacyl phosphatidylcholines as effectors of activity of
cytochrome P450SCC (CYP11A1). Modeling the structure of thefatty acyl chain region of cardiolipin, J. Biol. Chem. 271 (1996)
12840–12846.
[19] M.J. Headlam, R.C. Tuckey, The effect of glycerol on cytochrome
P450scc (CYP11A1) spin state, activity, and hydration, Arch. Bio-
chem. Biophys. 407 (2002) 95–102.
[20] C. Notredame, D.G. Higgins, J. Heringa, T-Coffee: a novel method
for fast and accurate multiple sequence alignment, J. Mol. Biol. 302
(2000) 205–217.
[21] W.C. Wimley, S.H. White, Experimentally determined hydrophobic-
ity scale for proteins at membrane interfaces, Nat. Struct. Biol. 3
(1996) 842–848.
[22] J. Cosme, E.F. Johnson, Engineering microsomal cytochrome P450
2C5 to be a soluble, monomeric enzyme. Mutations that alter aggre-
gation, phospholipid dependence of catalysis, and membrane binding,
J. Biol. Chem. 275 (2000) 2545–2553.
[23] S.A. Usanov, S.E. Graham, G.I. Lepesheva, T.N. Azeva, N.V.
Strushkevich, A.A. Gilep, R.W. Estabrook, J.A. Peterson, Probing
the interaction of bovine cytochrome P450scc (CYP11A1) with
adrenodoxin: evaluating site-directed mutations by molecular mod-
eling, Biochemistry 41 (2002) 8310–8320.
[24] A. Wada, M.R. Waterman, Identification by site-directed mutagenesis
of two lysine residues in cholesterol side chain cleavage cytochrome
P450 that are essential for adrenodoxin binding, J. Biol. Chem. 267
(1992) 22877–22882.
[25] T. Maniatis, E.F. Fritsch, J. Sambrook, Molecular Cloning. A Labo-
ratory Manual, Cold Spring Harbor Laboratory, New York, NY,
1982.
[26] S.T. Woods, J. Sadleir, T. Downs, T. Triantopoulos, M.J. Headlam,
R.C. Tuckey, Expression of catalytically active human cytochrome
P450scc in Escherichia coli and mutagenesis of isoleucine-462, Arch.
Biochem. Biophys. 353 (1998) 109–115.
[27] G.I. Lepesheva, T.N. Azeva, N.V. Strushkevich, T.B. Adamovich, T.S.
Cherkesova, S.A. Usanov, Comparative structural– functional charac-
terization of recombinant and natural adrenodoxin. Interaction with
cytochrome P450scc, Biochemistry (Mosc.) 64 (1999) 1079–1088.
[28] R.C. Tuckey, P.M. Stevenson, Properties of bovine luteal cytochrome
P-450scc incorporated into artificial phospholipid vesicles, Int. J. Bi-
ochem. 16 (1984) 497–503.
[29] G.I. Lepesheva, S.A. Usanov, Comparative structural and immuno-
chemical characterization of recombinant and natural cytochrome
P450scc (CYPXIAI), Biochemistry (Mosc.) 63 (1998) 224–234.
[30] T. Omura, R. Sato, The carbon monoxide-binding pigment of liver
microsomes: I. Evidence for its hemoprotein nature, J. Biol. Chem.
239 (1964) 2370–2378.
[31] R.C. Tuckey, K.J. Cameron, Side-chain specificities of human and
bovine cytochromes P-450scc, Eur. J. Biochem. 217 (1993) 209–215.
[32] E.M. Gillam, T. Baba, B.R. Kim, S. Ohmori, F.P. Guengerich, Ex-
pression of modified human cytochrome P450 3A4 in Escherichia
coli and purification and reconstitution of the enzyme, Arch. Bio-
chem. Biophys. 305 (1993) 123–131.
[33] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein meas-
urement with the folin phenol reagent, J. Biol. Chem. 193 (1951)
265–275.
[34] R.C. Tuckey, J. Sadleir, The concentration of adrenodoxin reductase
limits cytochrome P450scc activity in the human placenta, Eur. J.
Biochem. 263 (1999) 319–325.
[35] R.C. Tuckey, Z. Kostadinovic, P.M. Stevenson, Ferredoxin and cyto-
chrome P-450scc concentrations in granulosa cells of porcine ovaries
during follicular cell growth and luteinization, J. Steroid Biochem. 31
(1988) 201–205.
[36] D.B. Calhoun, J.M. Vanderkooi, S.W. Englander, Penetration of small
molecules into proteins studied by quenching of phosphorescence and
fluorescence, Biochemistry 22 (1983) 1533–1539.
[37] S.S. Lehrer, Solute perturbation of protein fluorescence. The quench-
ing of the tryptophyl fluorescence of model compounds and of lyso-
zyme by iodide ion, Biochemistry 10 (1971) 3254–3263.
[38] K. Gekko, S.N. Timasheff, Thermodynamic and kinetic examina-
M.J. Headlam et al. / Biochimica et Biophysica Acta 1617 (2003) 96–108108tion of protein stabilization by glycerol, Biochemistry 20 (1981)
4677–4686.
[39] Q. Wang, D. Cui, Q. Lin, Fluorescence studies on the interaction of a
synthetic signal peptide and its analog with liposomes, Biochim. Bio-
phys. Acta 1324 (1997) 69–75.
[40] P.A. Williams, J. Cosme, V. Sridhar, E.F. Johnson, D.E. McRee,
Microsomal cytochrome P450 2C5: comparison to microbial P450s
and unique features, J. Inorg. Biochem. 81 (2000) 183–190.
[41] I.A. Pikuleva, R.L. Mackman, N. Kagawa, M.R. Waterman, P.R. Ortiz
de Montellano, Active-site topology of bovine cholesterol side-chain
cleavage cytochrome P450 (P450scc) and evidence for interaction of
tyrosine 94 with the side chain of cholesterol, Arch. Biochem. Bio-
phys. 322 (1995) 189–197.
[42] K. Nakayama, A. Puchkaev, I.A. Pikuleva, Membrane binding and
substrate access merge in cytochrome P450 7A1, a key enzyme in
degradation of cholesterol, J. Biol. Chem. 276 (2001) 31459–31465.
[43] I.A. Pikuleva, A. Puchkaev, I. Bjorkhem, Putative helix F contributes
to regioselectivity of hydroxylation in mitochondrial cytochrome
P450 27A1, Biochemistry 40 (2001) 7621–7629.
[44] D. Murtazina, A.V. Puchkaev, C.H. Schein, N. Oezguen, W. Na-
navati, A. Nanavati, I.A. Pikuleva, Membrane–protein interactions
contribute to efficient 27-hydroxylation of cholesterol by mi-
tochondrial cytochrome P450 27A1, J. Biol. Chem. 17 (2002)
37582–37589.[45] R. Lange, P. Anzenbacher, S. Muller, L. Maurin, C. Balny, Interaction
of tryptophan residues of cytochrome P450scc with a highly specific
fluorescence quencher, a substrate analogue, compared to acrylamide
and iodide, Eur. J. Biochem. 226 (1994) 963–970.
[46] Y.K. Shin, C. Levinthal, F. Levinthal, W.L. Hubbell, Colicin E1 bind-
ing to membranes: time-resolved studies of spin-labeled mutants,
Science 259 (1993) 960–963.
[47] U. Gether, S. Lin, B.K. Kobilka, Fluorescent labeling of purified beta
2 adrenergic receptor. Evidence for ligand-specific conformational
changes, J. Biol. Chem. 270 (1995) 28268–28275.
[48] S. Jayasinghe, K. Hristova, S.H. White, Energetics, stability, and
prediction of transmembrane helices, J. Mol. Biol. 312 (2001)
927–934.
[49] J.A. Killian, G. von Heijne, How proteins adapt to a membrane–
water interface, TIBS 25 (2000) 429–434.
[50] A.S. Ladokhin, S.H. White, Protein chemistry at membrane interfa-
ces: non-additivity of electrostatic and hydrophobic interactions, J.
Mol. Biol. 309 (2001) 543–552.
[51] R. Koradi, M. Billeter, K. Wuthrich, MOLMOL: a program for dis-
play and analysis of macromolecular structures, J. Mol. Graph. 14
(1996) 51–55.
